RESEARCH TRIANGLE PARK, N.C., Dec. 3, 2014 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq:SCYX) today announced the appointment of Guy Macdonald and Marco Taglietti, M.D., to its Board of Directors. Mr. Macdonald currently serves as President and Chief Executive Officer of Tetraphase Pharmaceuticals, Inc., and Dr. Taglietti is former Executive Vice President of Research and Development and Chief Medical Officer of Forest Laboratories, Inc. In addition, the Company announced that Mounia Chaoui, Ph.D., has resigned from the Board of Directors.
"Guy Macdonald has a wealth of experience in drug development and commercialization, particularly with anti-infectives including antifungals, which will be invaluable to us as we continue the development of SCY-078," said Pamela J. Kirby, Ph.D., Chairman of the Board of SCYNEXIS. "Dr. Taglietti joins us with an impressive track record of ushering over 35 products across multiple indications to approval in the U.S. and globally. We look forward to working closely with Marco and Guy to continue our post-IPO transition. I would also like to thank Mounia for her contributions and the valuable support she provided to the company during her tenure."
Mr. Macdonald has been the President, Chief Executive Officer and board member for Tetraphase, a clinical-stage biopharmaceutical company developing novel antibiotics for multidrug-resistant infections, since 2008. Prior to that, he was the Executive Vice President of Operations at Idenix Pharmaceuticals, Inc. and held various positions at Merck & Co., most recently as Vice President for Anti-infective and Hospital Products. Mr. Macdonald joins SCYNEXIS' Board of Directors as an independent director, serving on the compensation committee.
Dr. Taglietti served as Executive Vice President, Research and Development and Chief Medical Officer of Forest Laboratories, Inc. and also as President of the Forest Research Institute until the company was acquired by Actavis, plc. Prior to joining Forest Labs, Dr. Taglietti was Senior Vice President, Head of Global Research and Development at Stiefel Laboratories, Inc. and held various positions with Schering-Plough Corporation where he last served as Vice President, Worldwide Clinical Research for Anti-infectives, Oncology, CNS, Endocrinology and Dermatology. He received his medical degree and board certifications from the University of Pavia in Italy. Dr. Taglietti joins SCYNEXIS' Board of Directors as an independent director, serving on the nominating and governance committee.
SCYNEXIS is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. For more information, visit www.scynexis.com.
Forward Looking Statement
Statements contained in this press release regarding matters that are expected to occur in the future are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in SCYNEXIS's filings with the Securities and Exchange Commission, including without limitation its most recent Quarterly Report on Form 10-Q and other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. SCYNEXIS undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
CONTACT: Media Relations Heather Savelle MacDougall Biomedical Communications Tel: 781-235-3060 E-mail: firstname.lastname@example.org SCYNEXIS, Inc. Contact Chuck Osborne Chief Financial Officer Tel: 919-544-8600 E-mail: email@example.com Investor Relations Jillian Connell The Trout Group LLC Tel: 646-378-2956 E-mail: firstname.lastname@example.orgSource:SCYNEXIS, Inc.